Cold chain for veterinary monoclonals: Librela, Cytopoint, and Solensia

Monoclonal antibodies were a human-medicine technology for decades. They are now front-line veterinary products — osteoarthritis pain control in dogs and cats, allergic dermatitis in dogs — and they have quietly imported human-biologic logistics into veterinary distribution. A practice that receives a case of Librela is receiving a protein therapeutic with a hard 2–8°C band and a do-not-freeze label, whether or not anyone in the building thinks of it as “a biologic shipment.”

Three products, one temperature band

The storage column is label language — Librela and Solensia from their FDA labels on DailyMed, Cytopoint from its Zoetis package insert. Cytopoint’s precautions section is the bluntest of the three about what transit abuse means:

“Store upright at 2°–8°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.”

Cytopoint package insert, Zoetis

That sentence is the entire cold chain brief. Both directions out of the band are named — heat on one side, freezing on the other — and the label offers no grace period, no excursion allowance, and no reconditioning path. What general tolerance exists for transport comes from the USP controlled-cold framework, not from these labels; see what 2–8°C actually permits in transit.

Same cold chain, different regulator

Here is the wrinkle most animal-health shipping content gets wrong, when it notices it at all. In the United States, veterinary therapeutics split between two federal agencies:

• FDA’s Center for Veterinary Medicine approves animal drugs. Librela and Solensia went this route; each label states “Approved by FDA” under its NADA number (141-562 and 141-546).
• USDA APHIS licenses veterinary biologics under the Virus-Serum-Toxin Act. The implementing regulation, 9 CFR §101.2, defines biological products to include vaccines, bacterins, allergens — and antibodies. Cytopoint, an antibody product positioned as an immunotherapeutic, is licensed there: its insert carries US Veterinary License No. 190 and points to USDA’s product database, productdata.aphis.usda.gov, for its licensing studies.

So Cytopoint is a USDA-licensed biologic while Librela and Solensia — the same modality, from the same company — are FDA-approved drugs. The distinction changes nothing about the packout and several things about the program around it: which agency’s rules govern the product, what the label must display (NADA number versus VLN), and which framework your quality documentation answers to. If you distribute both kinds, your receiving SOP should not assume one regulator’s paperwork. The full jurisdictional map — including where state pharmacy rules land on each — is in USDA vs. FDA veterinary cold chain regulation.

Antibodies are proteins — act accordingly

Why do all three labels converge on the same restrictions? Because monoclonal antibodies are large proteins in solution, and protein aggregation is one of the central, well-documented challenges of pharmaceutical development — a body of literature exists on its pathways and induction factors precisely because it must be controlled for a protein product to succeed (Mahler et al., Journal of Pharmaceutical Sciences, 2009). The storage restrictions on these labels — the band, the freeze prohibition, the light and heat warnings — are the manufacturer’s stability program translated into instructions.

We will not tell you what happens to bedinvetmab at 20°C for six hours, because nobody outside Zoetis has that data and the label does not publish it. That is the point: with a biologic, the label’s storage statement is the only stability envelope you are entitled to rely on. Anyone quoting product-specific hour-by-degree tolerances for these products is inventing them. Design the lane so the question never gets asked — and if a shipment does land out of band, the disposition framework is the excursion-adjudication process plus a call to the manufacturer, not a guess.

The lane: distributor to clinic, with mail-order growing at the edges

These are clinic-administered injections — each label restricts use to, or under the supervision of, a veterinarian — so the dominant flow is distributor-to-practice: multi-vial cases, weekly or twice-weekly deliveries, received by a technician between appointments. Veterinary pharmacies also dispense into this space, which puts the same vials into parcel-network shipments with residential-style dwell. Either way, the receiving end is the weak point. A case that sits on a loading dock from Friday to Monday fails at 2–8°C just as surely as a porch parcel in August.

What a receiving practice should actually do: check the shipment immediately on arrival, not at the next appointment; confirm product is cold to the touch and refrigerant is not fully spent; refrigerate at once, in the box (Librela’s label makes the carton part of the light protection); and route any doubt to the distributor or manufacturer before the case goes into stock. For shippers, the design brief is the standard one — tested hold beyond worst-case transit, freeze floor engineered out, no weekend exposure. Meridian’s M-48 and M-72 are chamber-tested at 2–8°C for exactly this class of product; the full packout anatomy is in the refrigerated pet medication guide.

Frequently asked questions